Novo Agrees to 2.6 Billion Dollar Weight Loss Pill Deal

Novo Nordisk will pay up to 2.6 billion dollars to Jiangsu Hengrui Pharmaceuticals for rights to an experimental weight loss pill. The agreement strengthens the drugmaker's pipeline against competitors in the growing GLP-1 market.

Xurve View
Insights:
The logo of Jiangsu Hengrui Pharmaceuticals stands outside its office in Shanghai, China June 11, 2026. REUTERS/Andrew Silver

NOVO NORDISK A/S-B agreed to pay up to $2.6 billion to JIANGSU HENGRUI PHARMACEUT-H on Tuesday morning for global rights to an experimental weight-loss pill. The transaction expands the Denmark-based drugmaker's pipeline through a second GLP-1 partnership in China. The move helps Novo counter market pressure from competitors like ELI LILLY & CO as key patents approach expiration.